Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Pfizer launches lupus study with 23andMe

Aims to enroll 5,000 patients into new geneticresearch study

23andMe Pfizer lupus

Pfizer has begun recruiting patients into the lupus study it is running with online personalised genetics company 23andMe.

The companies, which will also work with the Lupus Research Institute, aim to enroll 5,000 individuals with systemic lupus erythematosus, with patient recruitment expected to be completed by mid-2016.

Belen Carrillo-Rivas, head of research and development innovation projects, BioTherapeutics Research & Development, Pfizer, said: "Pfizer is committed to bringing forward new treatments for patients suffering from lupus.

"By enhancing our understanding of the underlying biology of the disease, we hope to better support our clinical research activities and development programmes."

The study will look to uncover possible underlying genetic causes of lupus, specifically those associated with the onset, progression, severity and response to treatments for lupus.

Margaret Dowd, president and CEO of non-profit organisation the Lupus Research Institute, said: "Lupus is an unpredictable and devastating disease for which the treatments can be as debilitating as the disease itself.

“Research on human genetics has enormous potential to deliver information that can help improve lupus treatment. The more insights that researchers can gain, the faster safer drugs can be developed.”

In addition to genetic information and survey questions, 23andMe will also incorporate data from participants' medical records, with their consent, into the study.

This data will then be used in the analysis of longitudinal surveys with participants over the course of a year.

Anne Wojcicki, 23andMe CEO and co-founder, said: "The ability to effectively personalise treatments for lupus patients is limited, due in large part to our incomplete understanding of the disease. We hope to change that by studying human genetics alongside environmental and health history factors to ultimately help inform better treatment options for lupus patients."

The study forms the first concrete output from 23andMe's lupus collaboration with Pfizer. Signed in January, this added to the partners' existing research agreement in ulcerative colitis and Crohn's disease.

Meanwhile, 23andMe added Genentech to its list of pharma partners at the start of this year, forging a research pact to focuses on generating whole genome sequencing data for about 3,000 people with Parkinson's disease.

18th May 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...